针对男性优势型肝细胞癌的雄激素受体靶向治疗的改进。
Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma.
机构信息
Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA; Department of Pharmacology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, 675 Hoes Lane, Piscataway, NJ 08854, USA.
Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA; Department of Medicine, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, 125 Paterson Street, New Brunswick, NJ 08901, USA.
出版信息
Drug Discov Today. 2021 Jun;26(6):1539-1546. doi: 10.1016/j.drudis.2021.02.001. Epub 2021 Feb 6.
Hepatocellular carcinoma (HCC) is the predominant form of liver cancer and a leading cause of cancer deaths worldwide. HCC is a male-dominant cancer with a male:female ratio of up to 7:1. The androgen receptor (AR) is the male hormone receptor known as a major oncogenic driver of prostate cancer. Although AR has been linked to the sexual dimorphism of HCC, clinical trials with AR-targeted agents failed to generate survival benefits. Recent studies provide new insights into the role of AR in liver tumorigenesis and therapeutic responses. Herein, we review current understanding of AR signaling in HCC and feedback mechanisms that limit response to AR blockade. New AR-targeting strategies that might improve outcomes in HCC therapies are also discussed.
肝细胞癌（HCC）是肝癌的主要形式，也是全球癌症死亡的主要原因。HCC 是一种男性为主的癌症，男女比例高达 7:1。雄激素受体（AR）是男性荷尔蒙受体，被认为是前列腺癌的主要致癌驱动因素。尽管 AR 与 HCC 的性别二态性有关，但 AR 靶向药物的临床试验未能产生生存获益。最近的研究为 AR 在肝肿瘤发生和治疗反应中的作用提供了新的见解。本文综述了目前对 HCC 中 AR 信号通路的认识，以及限制 AR 阻断反应的反馈机制。还讨论了可能改善 HCC 治疗效果的新的 AR 靶向策略。
Zotero 插件